Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Journal Guam.
Press releases published on September 24, 2025
Ultrack Systems Inc. (OTC: MJLB) Subsidiary Better Pets Secures Canadian Trademark Registration and Advances U.S. Trademark Application
TORONTO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Ultrack Systems Inc. (OTC: MJLB) (“Ultrack” or the “Company”), through its wholly owned subsidiary Better Pets (Better Health Sciences for Pets Corp.), is pleased to announce that it has officially secured a …
Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1
Data highlights ability of Akari’s ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate cancer progression No current therapies have proven to be effective in AR-V7 driven tumors BOSTON …
OneMedNet Expands Into $1.5B Healthcare Data Annotation Market With MedCase
MINNEAPOLIS, Sept. 24, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leader in AI-powered Real-World Data (RWD), announced a strategic partnership with Medcase, a worldwide network of …
Sparrow Pharmaceuticals Announces $95 Million Series B Financing to Advance Targeted Therapy for Type 2 Diabetes
PORTLAND, Ore., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the close of a $95 million Series B financing. The round was co-led by RA Capital Management and Forbion with …
Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients
SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- via IBN -- Sapu Nano, developer of Deciparticle™, today announced that it has received approval from Australia’s Human Research Ethics Committee (HREC) to begin enrolling patients in a Phase 1 human clinical …
Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress
BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a …
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)
FLORHAM PARK, N.J. and LONDON and CHARLOTTESVILLE, Va., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (“Cellectar”) (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the …
Er-Kim Enters Commercialization Agreement with Sentynl Therapeutics for Nulibry® (fosdenopterin) and Zokinvy® (lonafarnib), Targeting Ultra-Rare Diseases
ATHENS, Greece and SOLANA BEACH, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in EMEA region, today announced that it has signed an agreement with …
Leading CDMO Enhances cGMP Lab Infrastructure to Strengthen Position
Expanded microbiology lab and analytical chemistry capabilities position Ritedose for accelerated growth. $17+ million investment fuels innovation and scale in drug development. COLUMBIA, S.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- The Ritedose Corporation is …
EGI Launches Next-Generation HD-EEG Platform to Advance Understanding of Brain Function and Stimulation
MINNEAPOLIS, Sept. 24, 2025 (GLOBE NEWSWIRE) -- EGI has unveiled the Geodesic EEG System 500, the world’s first intelligent ecosystem for precision brain research and translational research, redefining how neuroscientists capture and analyze the brain’s …
HealthChannels Reveals Family of Brands to Bring Point-of-Care Solutions to the Most Pressing Secular Challenges in Healthcare
FORT LAUDERDALE, FLORIDA, Sept. 24, 2025 (GLOBE NEWSWIRE) -- HealthChannels is pleased to announce its expanded portfolio, including four specialized brands: Enabli Health, ScribeAmerica, Speke AI, and HealthCareU. This comprehensive suite of solutions …
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx’s Proposed Strength of Preservative-Free Ketamine
Suitability Petition is required for shift from multidose packaging of ketamine to single-patient dose preservative free ketamine Granting of Suitability Petition enables re-filing of Abbreviated New Drug Application (ANDA) for NRx’s patent-pending …
MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent
THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced non-small cell lung cancer (NSCLC) CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) …
Aging in Place, Limited Access to Medical Care and Economic Insecurity Threaten U.S. Senior Health
ORANGE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Aging in place (64%), limited access to medical care (60%), and economic insecurity (51%) were cited by U.S. seniors as the top three barriers to their overall health, according to the 2025 Social Threats …
BPGbio Sponsors MitoAction Energy Walk at Boston’s Franklin Park Zoo on September 27th, 2025
BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma focused on mitochondrial biology and protein homeostasis, today announced its sponsorship of the MitoAction Energy Walk at Boston’s Franklin Park …
Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research
SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, today announced it has entered into an …
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
NAARDEN, The Netherlands and MIAMI, Sept. 24, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients …
Proscia to Expand Pathology AI Capabilities with Virtual Staining
PHILADELPHIA and LOS ANGELES, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Proscia®, a pathology AI company, is introducing virtual staining in its Concentriq® software platform to help laboratories reduce the costs associated with traditional chemical methods and …
Kura Oncology to Participate in Upcoming Investor Conference
SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled …
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) …